Table 3.
Number of antibody-based biotherapeutic products available for different regular maintenance dose regimens with respect to routes of administration and therapeutic areas*.
| Therapeutic Area | Intravenously Administered |
Subcutaneously Administered |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| QW | Q2W | Q3W | Q4W | ≥Q5W | QW | Q2W | Q3W | Q4W | ≥Q5W | |
| Autoimmunity | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cardiovascular Diseases | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 |
| Cardiology | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Drug Overdose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematology | 3 | 5 | 3 | 4 | 1 | 1 | 0 | 0 | 1 | 0 |
| Hereditary Diseases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Immunology | 2 | 5 | 2 | 6 | 4 | 1 | 6 | 0 | 5 | 5 |
| Infectious Diseases | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inflammation | 1 | 2 | 1 | 2 | 1 | 0 | 1 | 0 | 1 | 0 |
| Neurology | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 3 | 1 |
| Oncology | 6 | 11 | 9 | 4 | 1 | 0 | 0 | 0 | 0 | 0 |
| Ophthalmology | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Osteology | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Pulmonary | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rheumatology | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
*A comparison of maintenance dose regiments for different therapeutic areas, separated by route of administration. Note that Hematology has 16 i.v. maintenance dosing options while only 2 s.c. options. Oncology has 31 i.v. dosing options and no s.c. options. Also, QW and Q3W are rare for s.c. administered products.